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ABSTRACT
The tumor suppressor protein p53 may have
other roles and functions in addition to its well-
documented ability to serve as a sequence-speci®c
transcriptional activator in response to DNA
damage. We showed previously that p53 can block
the replication of polyomavirus origin-containing
DNA (Py ori-DNA) in vitro when p53 binding sites
are present on the late side of the Py ori. Here we
have both further extended these observations and
have also examined whether p53 might be able to
bind directly to and inhibit the replication of
damaged DNA. We found that p53 strongly inhibits
replication of g-irradiated Py ori-DNA and such
inhibition requires both the central DNA binding
domain and the extreme C-terminus of the p53
protein. An endogenous p53 binding site lies within
the Py origin and is required for the ability of p53 to
block initiation of replication from g-irradiated Py
ori-DNA, suggesting the possibility of DNA looping
caused by p53 binding both non-speci®cally to sites
of DNA damage and speci®cally to the endogenous
site in the polyomavirus origin. Our results
thus suggest the possibility that under some
circumstances p53 might serve as a direct regulator
of DNA replication and suggest as well an
additional function for cooperation between its two
autonomous DNA binding domains.
INTRODUCTION
The p53 tumor suppressor protein accumulates in the nuclei of
cells in response to various forms of stress including DNA
damage. Once stabilized, p53 can arrest cells in G1 and/or G2
or cause apoptosis, through its functions as a sequence-speci®c
transcriptional regulator (for reviews, see 1±3). The p53
protein possesses structural domains that are characteristic of
transcriptional activators including an activation region at its
N-terminus, a sequence-speci®c DNA binding region within
its central portion and an oligomerization domain within its
C-terminal region. In addition to genes regulating cell cycle
and cell death, p53 can stimulate the transcription of genes
encoding products that can affect both DNA synthesis and
repair. For example, one of the most well studied p53 target
genes is p21/CIP1/WAF1, which can both inhibit cyclin-
dependent kinases (4) and also bind to and inactivate PCNA,
which plays an essential role in DNA replication by facilitat-
ing processive DNA synthesis by polymerase d (5). Moreover,
p53 activates both the RRM2B/p53R2 gene (6) and the DDB2
(damage-speci®c DNA binding protein 2) gene (7,8) that each
plays distinct roles in DNA repair.
Although as mentioned above p53 protein embodies the
classical features of a sequence-speci®c transcriptional
activator, it has one property that is rather unique, which is
that it possesses a second essentially autonomous DNA
binding region at its extreme C-terminus (9). This region of
the protein has been shown to facilitate and be required for the
interaction of p53 with various forms of damaged or altered
DNA including deletion/insertion mismatches, DNA ends, as
well as double- and single-strand breaks (for a review, see 10).
The function of this region is not fully clari®ed and it has also
been shown to be able to regulate the mode by which the
central region recognizes DNA (for a review, see 11).
Although p53 is clearly involved in regulating the tran-
scription of numerous targets, there are several lines of
evidence suggesting that p53 may play transcription-
independent roles in cells as well. Some mutant p53 proteins
that have lost transcriptional transactivation capacity retain
their ability to arrest cell growth to varying extents (12±16).
Conversely, loss of growth suppressor function has been
reported in some p53 mutants, which retain transcriptional
activity (17±19). A recent study by Jaks et al. (20) showed that
when cells are treated with the DNA-damaging drug
camptothecin, p53 accumulation rather than the transactiv-
ation of p21 is required for the G1 arrest, strongly suggesting
that p53 may play transcription-independent role(s) in cells. In
fact it is possible that under some conditions p53 may play a
direct role in regulating DNA synthesis. Various experimental
results suggest that p53 protein may inhibit DNA replication
in a transcription-independent manner. The C-terminally
truncated form of p53 protein, p53DC30, which is also the
DNA binding active form of p53 protein, was reported to
inhibit Xenopus nuclear DNA replication in a transcription-
independent manner (21). p53 may inhibit the initiation of
DNA replication directly by binding to RP-A (22±24), which
is a single-stranded DNA binding protein required for DNA
replication. p53 protein also blocks the replication of SV40
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DNA in vitro by binding to and inactivating the SV40 large T
antigen (25±27). Additionally, although p53 protein does not
bind to or inhibit polyoma large T antigen, it is also able to
inhibit the replication of polyomavirus origin-containing
DNA (Py ori-DNA) in vitro although in this case it is
necessary for p53-speci®c binding sites to be present in the
template origin-containing plasmid (28).
There have also been reports supporting the possibility of
role(s) for p53 in regulating and responding to altered DNA
replication in vivo. When DNA synthesis is blocked, p53
inhibits entry into mitosis (29), and in several cell lines p53 is
transcriptionally dysfunctional when DNA synthesis is
blocked (30). p53 protein prevents mammalian DNA reduplic-
ation, following the release from the mitotic spindle check-
point, in a transcription-independent manner (13). In addition,
p53 inhibits the replication of Py and papillomavirus origin-
containing DNAs in a cell-speci®c way: p53 represses
replication of both viral origins in human and Chinese hamster
cells, but fails to do so in mouse cells (31±33). Further
evidence supporting the possibility for a direct interaction
between p53 and the DNA replication machinery is provided
by the observations that p53 is localized to foci of replication
in the nuclei of herpes virus-infected cells (34) and that p53 is
imported into the nucleus of Xenopus oocyte upon fertiliz-
ation, although the ®rst 12 rapid cell cycles occur without
transcription of the genome (35).
To continue to explore possible alternative roles and
functions of p53, in this study we tested the possibility that
p53 affects the replication of damaged DNA templates. We
found that p53 can block the initial stage of replication of a
g-irradiated plasmid containing the Py replication origin. Such
inhibition requires both speci®c binding by the p53 core
domain and non-speci®c binding by its C-terminus. We
discuss the implications of our ®ndings including the
likelihood that the effects seen require DNA looping by p53.
MATERIALS AND METHODS
Plasmids
Vw16PyCAT contains 16 p53 binding sites (RGC; refers to
the p53 binding site in the ribosomal gene cluster) on the late
side of the Py replication origin and is the same plasmid used
by Miller et al. and Vogelstein and Kinzler in their respective
studies (28,36). pBE102 has been described previously and
contains the A2 strain of Py wild-type sequences extending
from the BclI site at nucleotide 5022 to the EcoRI site at
nucleotide 1562 inserted into a pML vector containing neo
coding sequences (37). To construct Vw16PyCATBSM1
(BSM: p53 binding site mutant) and Vw16PyCATBSM2,
oligonucleotides 5¢ CGCCTCCAAGGCGCCAGTTCTATT-
TTGATAAATTGCCTCTGGAAGC 3¢ and 5¢ CGCCTCCA-
AGGCGCCAGACATGTTTGGACAAGTTCCCTCTGGA-
AGC 3¢ were used as the forward primer, respectively, to
mediate the PCR-directed mutagenesis. Oligonucleotide 5¢
CCCTCGAGGTCGACGGTATCG 3¢ (a pBluescript II SK
sequence) was used as the reverse primer. Similarly, the same
two forward primers and oligonucleotide 5¢ ACAGGAG-
ATCCTGCCCCGGCA 3¢ (a neo sequence), as the reverse
primer, were used to construct pBE102BSM1 and
pBE102BSM2. PCR products of 588 and 814 bp were
recovered and digested with PstI/NarI or NarI, respectively.
The 140 and 621 bp fragments were ligated with their
respective vectors, PstI/NarI digestion product of Vw16Py-
CAT and the 3.9 kb fragment recovered from NarI digestion of
pBE102.
Proteins
Baculovirus-expressed HA-tagged p53 protein was puri®ed as
described (38). Active HA±p53 was immunopuri®ed using
PAb421 antibody, while latent HA±p53 and HA±p53DC30
were immunopuri®ed using mAb12.CA5 antibody. Oxidized
HA±p53 was prepared similarly except that extraction, elution
and dialysis were done in buffers lacking DTT. Py large T
antigen was immunopuri®ed from baculovirus-infected Sf21
cells as described previously (26).
Replication of Py DNA in vitro
Extracts of mouse FM3A cells were prepared as described
(26). Standard replication reaction mixtures (50 ml) contained
40 mM creatine phosphate (pH 8.0), 7 mM MgCl2, 0.5 mM
DTT, 4 mM ATP, 200 mM each CTP, UTP and GTP, 100 mM
each TTP, dGTP and dCTP, 20 mM dATP, 0.03 mM
[a-32P]dATP and 100 mg of creatine kinase/ml. 300 ng
template plasmid, 0.5±1 mg Py T antigen, FM3A cell extract
(300±400 mg of protein) and reaction mixtures were incubated
at 33°C for 3 h. Replication products were analyzed by either
acid precipitation or phosphoimaging analysis of agarose gels,
following DpnI treatment of puri®ed replication products,
with a Molecular Dynamics PhosphoImager. For replication
of g-irradiated pBE102, puri®ed pBE102 plasmid was ®rst
g-irradiated in water at a ®nal concentration of 300 ng/ml and
then used as template in replication reactions.
Electrophoretic mobility shift assay
EMSA was performed as described (39). The oligonucleotide
probe containing 3-fold RGC site is as follows: 5¢
AATTCCCCGGATCGCCTTGCCTGGACTTGCCTGGCC-
TTGCCTTTTCGATCCGGGG 3¢. The oligonucleotide con-
taining wild-type or mutant p53 binding site was created by
digesting the 621 bp NarI digestion product of pBE102,
pBE102BSM1 or pBE102BSM2 with HinfI, and the resulting
411 bp oligonucleotide fragment, which represents Py
sequence from nucleotide 5076 to 89, was gel-puri®ed and
end-labeled. Reaction mixtures (20 ml) contained 4 ml of 53
EMSA buffer [100 mM HEPES (pH 7.9), 125 mM KCl,
0.5 mM EDTA, 50% glycerol, 10 mM MgCl2], 1 ml of 40 mM
spermidine, 1 ml of 10 mM DTT, 1 ml of 0.5% NP-40, 1 ml of
60 mg/ml double-stranded poly(dI±dC), 2 ml of 1 mg/ml
bovine serum albumin, 1 ng of 32P-labeled probe DNA and
proteins as indicated. Reaction mixtures were incubated for
20 min on ice and then subjected to electrophoresis on 4%
native polyacrylamide gels at 4°C. Gels were dried and
autoradiographed.
RESULTS
p53 requires its sequence-speci®c DNA binding function
to inhibit the in vitro replication of polyoma origin DNA
We reported previously (28) that wild-type human p53
strongly inhibits the replication of a DNA plasmid
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(Vw16PyCAT) containing multiple copies of a p53 binding
site (RGC) cloned adjacent to the late side of the Py origin,
while the replication of a DNA plasmid containing mutated
binding sites, is not affected by p53 (please refer to Fig. 8 for
depiction of Py ori and early and late sides). Moreover, in that
study two tumor-derived core domain p53 mutants, Trp-248
and His-273, were shown to be unable to inhibit the replication
of Vw16PyCAT. These ®ndings implicated sequence-speci®c
DNA binding by p53 as a requirement for its ability to repress
Py ori-DNA replication. To con®rm and extend these studies
we examined the ability of various forms of p53, each
differing in their ability to bind to DNA, to inhibit the
replication of Vw16PyCAT in mouse FM3A cell extracts.
Note that although FM3A cells have been reported to contain
wild-type p53 whose protein levels are increased after UV
irradiation (40), the extracts used in our experiments are from
unstressed cells and contain little or no detectable p53 (data
not shown).
It was shown previously by Jayaraman et al. (39) that
N-terminally HA-tagged p53 protein that had been immuno-
puri®ed using an af®nity column containing the C-terminal-
speci®c monoclonal antibody PAb421, HA±p53 [PAb421], is
more active in sequence-speci®c DNA binding than a
similarly puri®ed p53 protein preparation (HA±p53 [¯u]) in
which the af®nity column contained the HA antibody
(mAb12.CA5). The basis for this difference is not fully
understood but may be related to the observations that
interactions of PAb421 with the p53 C-terminus can in some
cases stimulate its ability to bind to DNA (41). It has also been
shown that p53 puri®ed in the absence of reducing agents
(HA±p53 [¯u, ±DTT]) is inert in DNA binding (39,42,43). In
contrast, as is well-documented, p53 lacking the C-terminus
(HA±p53DC30 [¯u]) can bind extremely well to DNA (41,44).
These four different forms of HA-tagged p53 were prepared
and tested for their ability to affect replication of
Vw16PyCAT Py ori-DNA. As expected, equivalent quantities
of these p53 protein preparations, HA±p53DC30 [¯u], HA±
p53 [PAb421], HA±p53 [¯u] and HA±p53 [¯u, ±DTT], have
descending af®nities for an oligonucleotide probe, which
contains three copies of the RGC site (Fig. 1A and B). The
abilities of the different forms of p53 protein to inhibit the
replication of Vw16PyCAT in vitro as measured both by
incorporation of labeled deoxynucleotide into progeny DNA
(Fig. 1C) and DpnI-resistant DNA detected on a 1% vertical
agarose gel (Fig. 1D) re¯ected their relative abilities to bind to
DNA. Note that the presence of DpnI-resistant DNA sug-
gested that all the dAMP incorporation measured was
produced by replication synthesis. We then tested a core
domain `hot-spot' p53 mutant, HA±p53His±175 [¯u], as well as
an N-terminally mutated form of p53, HA±p53Gln±22/Ser±23
[¯u], which has been shown to be defective in transactivation
of p53 target genes but active in sequence-speci®c DNA
binding (45). As shown in Figure 2, both wild-type HA±p53
[¯u] and HA±p53Gln±22/Ser±23 [¯u] bound to the oligonucleotide
probe containing three copies of RGC sites to similar extents,
while, as expected, HA±p53His±175 [¯u] failed to interact with
the RGC sites. Correspondingly, wild-type HA±p53 [¯u] and
HA±p53Gln±22/Ser±23 [¯u] inhibited replication of Vw16PyCAT
in a dose-dependent fashion while HA±p53His±175 [¯u] failed
to do so. Our results thus strongly support the conclusion that
the essential feature required for p53 to block DNA replication
is speci®c binding to the Py ori-DNA template. Furthermore,
the fact that HA±p53Gln±22/Ser±23 [¯u] functions like wild-type
HA±p53 [¯u] in inhibiting the replication of Vw16PyCAT
suggests that this inhibition does not require interaction of the
N-terminus with cellular proteins that bind to its activation
domain.
A p53 binding site in the Py origin region is required for
the inhibition of the replication of Vw16PyCAT by p53
During the course of our earlier study a consensus p53 binding
site on the early side of the Py core origin, spanning
nucleotides 66±85, was identi®ed and we showed that p53
can protect this site from DNase I digestion (28). We did not,
however, determine whether the interaction of p53 with this
site was required for p53 to block replication of constructs
containing binding sites on the late side of the origin. To
determine the role of this endogenous p53 binding site in the
inhibition of the replication of Vw16PyCAT by p53, two
mutant plasmids, Vw16PyCATBSM1 (BSM: p53 binding site
mutant) and Vw16PyCATBSM2, were constructed that have
mutated forms of this endogenous p53 binding site (Fig. 3A).
In PyORI-BSM1 the two sets of essential C and G nucleotides
from the p53 consensus sequence were mutated to T and A,
while PyORI-BSM2 was altered to conform to a `perfect' p53
consensus sequence. To test the af®nity of p53 protein to the
three different sequences, we used two different approaches.
Figure 3B shows the result of a gel mobility shift assay in
which HA±p53 [¯u] bound end-labeled 411 bp oligonucleo-
tide fragments excised from the respective Vw16PyCAT
derivatives (Py nucleotide 5076±89). Figure 3C shows a gel
mobility shift assay with the three RGC sites containing
oligonucleotide (as in Fig. 1B) as the labeled probe
and increasing amounts of plasmid Vw16PyCAT,
Vw16PyCATBSM1 or Vw16PyCATBSM2 as competitor
DNAs. As expected, the results of both methods show that
HA±p53 [¯u] protein has the highest af®nity to PyORI-BSM2
and a minimal af®nity to PyORI-BSM1.
We then used the three different plasmids as the template in
the Py ori-DNA replication assay. Interestingly, while in the
absence of p53, Vw16PyCATBSM2 had a replication ef®-
ciency close to that of Vw16PyCAT, Vw16PyCATBSM1
replicated 3±4-fold more ef®ciently than the other two
plasmids (data not shown). Since the endogenous p53 binding
site is located between two T antigen binding consensus
pentanucleotides spanning nucleotides 62±66 and 95±99, it
may be that the weaker T-A base pairs constructed in PyORI-
BSM1 make it easier for T antigen to unwind the origin DNA.
In the presence of HA±p53 [¯u] protein the replication of
Vw16PyCATBSM2 was inhibited even more ef®ciently than
the replication of Vw16PyCAT, while the replication of
Vw16PyCATBSM1 was not affected at all by HA±p53 [¯u]
(Fig. 3D). Our results thus show that the ability of p53 to
inhibit the replication of Vw16PyCAT closely correlates to the
af®nity of p53 for the endogenous p53 binding site, and they
further support the conclusion that p53 inhibits the replication
of Vw16PyCAT in a DNA binding-dependent manner.
p53 inhibits the replication of radiation damaged, but
not intact, pBE102
It was of interest to expand these observations to ask what
might be considered a more physiologically relevant question,
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which is whether p53 can block the replication of damaged
DNA. This is hypothetically feasible because p53 contains
another autonomous DNA recognition region within its
C-terminal domain that binds to several forms of DNA
including DNA damaged by irradiation (for a review, see 10)
as well as DNA with single or 4 nt gaps (J.Ahn, J.Zhou, and
C.Prives, unpublished data). Thus, would DNA damage
randomly introduced into the Py genome allow replication
of Py DNA to be inhibited by p53? To this end, we g-irradiated
a plasmid pBE102, which contains the wild-type Py sequence
extending from nucleotide 5022 to 1562 (37), and examined
the ability of p53 to inhibit the replication of this plasmid.
pBE102 contains the endogenous p53 binding site on the early
side of the origin but lacks additional p53 binding sites and its
replication is not affected by p53 (26). As shown in Figure 4A
and B, increasing doses of ionizing radiation reduced the
ability of pBE102 to serve as a replication template. When
HA±p53 [¯u] was added to the reaction mixtures, replication
of pBE102 that had been pre-treated with the same doses of
g-irradiation was further inhibited in a p53-concentration-
dependent manner.
Although in the presence of T antigen, the majority of
dAMP incorporation in vitro using g-irradiated pBE102 as a
template is likely due to replication synthesis, the possibility
cannot be excluded that repair synthesis as detected by labeled
deoxynucleotide incorporation could also be inhibited by p53.
Therefore, DpnI resistance of the replication products was
examined in order to distinguish replication synthesis from
Figure 1. p53 inhibits replication of Py ori-DNA in a sequence-speci®c DNA binding-dependent manner. HA-tagged human p53 was puri®ed from infected
insect cells on either a PAb421 column HA±p53 [PAb421], or a mAb12.CA5 column HA±p53 [¯u] with or without DTT. Similarly, ¯u-tagged p53DC30
(1±363) was puri®ed on a mAb12.CA5 column. (A) 300 and 600 ng of each protein were run on a SDS±PAGE gel which was silver stained. M lane contains
molecular mass marker proteins. (B) Increasing amounts of each protein (10, 20 or 40 ng) were added to EMSA reaction mixtures including as probe 32P-end-
labeled oligonucleotide containing three RGC p53 binding sites. (C) Increasing amounts (200, 400 or 600 ng) of each type of p53 protein were added to
reaction mixtures containing 300 ng of Vw16PyCAT plasmid DNA and 600 ng of Py large T antigen. Replication was measured by acid precipitation of
replicated DNA. The percentages represent the average of ®ve separate experiments with bars showing the sample standard error. (D) Replication products
from one experiment were puri®ed and analyzed by DpnI digestion. C: control.
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repair synthesis. Interestingly, HA±p53 [¯u] inhibited exclu-
sively replication synthesis, while repair synthesis was not
affected (Fig. 4C). To verify this result, we further examined
the ability of HA±p53 [¯u] to affect the repair of g-irradiated
pBE102 in the absence of T antigen where virtually all of the
nucleotides were incorporated at sites of repair synthesis and
here too HA±p53 [¯u] did not affect these activities (Fig. 4D).
Thus, our results show that p53 can speci®cally inhibit the
replication but not the repair of a radiation damaged Py
ori-DNA template.
Since the C-terminus is required for the interaction of p53
with irradiated DNA (46), we tested whether this region is
necessary for the ability of p53 to block the replication of
damaged ori-DNA. As shown in Figure 5A, among the four
different forms of p53 protein used in Figure 1, only HA±p53
[PAb421] and HA±p53 [¯u] inhibited the replication of
g-irradiated pBE102. In fact HA±p53 [¯u] was relatively more
effective in blocking the synthesis of damaged ori-DNA than
of intact ori-DNA containing RGC binding sites. Neither HA±
p53DC30 [¯u], nor the oxidized HA±p53 [¯u, ±DTT],
Figure 2. Wild-type and an N-terminal mutant p53Gln22/Ser23, but not the central core domain mutant p53His175, inhibit the replication of Py ori-DNA.
(A) Baculovirus-expressed wild-type and mutant HA±p53 proteins (300 and 600 ng) were immunopuri®ed on a mAb12.CA5 column and analyzed on a silver
stained SDS±polyacrylamide gel as indicated. M lane contains molecular marker proteins. (B) Increasing amounts of each protein (10, 20 and 40 ng) were
added to EMSA reaction mixtures containing end-labeled RGC probe as in Figure 1. (C) Effects of WT HA±p53 [¯u], HA±p53Gln22/Ser23 [¯u] and HA±
p53His175 [¯u] on the replication of plasmid Vw16PyCAT were compared. Replication was measured by acid precipitation of replicated DNA. The
percentages represent the average of three separate experiments with bars showing the sample standard error.
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inhibited the replication of g-irradiated pBE102. Thus, while
the C-terminus of p53 is not required to block the replication
of plasmids bearing p53 binding sites, it is indispensable for
p53 inhibition of replication of damaged plasmids. The fact
that HA±p53 [¯u, ±DTT] was inert, however, suggested that
sequence-speci®c DNA binding by p53 is also a component of
its repressive effect on replication of damaged ori-DNA. This
conclusion is supported by the experiment described below.
Figure 3. The endogenous p53 binding site in the Py origin is required for p53 to inhibit the replication of Py ori-DNA. (A) Sequence of wild-type Py
genome spanning Py nucleotides 66±85 (the endogenous p53 binding site, PyORI-BS) and two mutant forms of this sequence (PyORI-BSM1 and PyORI-
BSM2) are shown below the p53 consensus binding sequence. Bold characters show the mutated deoxynucleotides. (B) Increasing amounts of puri®ed
HA±p53 [¯u] (10, 20 and 40 ng) were added to EMSA reaction mixtures including end-labeled 411 bp oligonucleotide fragments spanning Py nucleotides
5076±89 containing either the wild-type Py sequence, PyORI-BSM1 or PyORI-BSM2 as indicated. (C) Increasing amounts of unlabeled plasmids
Vw16PyCAT, Vw16PyCATBSM1 or Vw16PyCATBSM2 (100, 300 and 900 ng) were added to EMSA reaction mixtures containing 20 ng of puri®ed HA±
p53 [¯u] protein and 1 ng of end-labeled RGC oligonucleotide probe. (D) Effects of HA±p53 [¯u] on the replication of Vw16PyCAT, Vw16PyCATBSM1
and Vw16PyCATBSM2 were compared.
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Inhibition of the replication of g-irradiated pBE102
requires the endogenous p53 binding site
The fact that the endogenous p53 binding site on the late side
of the origin is required for the inhibition of replication of
plasmids bearing p53 binding sites, led to the question as to
whether this site is also required for the inhibitory effect of
p53 on g-irradiated pBE102. To test this, plasmids
pBE102BSM1 and pBE102BSM2 were constructed, which
have the endogenous p53 binding site mutated to BSM1 and
BSM2, respectively (as shown in Fig. 3A). Indeed, in contrast
to wild-type or pBE102BSM2, the replication of g-irradiated
pBE102BSM1 was not inhibited by HA±p53 [¯u] (Fig. 5C),
indicating that the endogenous p53 binding site is required
for p53 to inhibit the replication of radiation damaged Py
ori-DNA.
It remained possible that the ability of p53 to bind to
irradiated DNA might facilitate its ability to inhibit replication
of pBE102 by a mechanism that does not require irradiation of
the pBE102 plasmid itself. Thus, p53 might bind simul-
taneously to an irradiated plasmid with its C-terminus and to
another unirradiated plasmid through interaction of its central
domain with the endogenous binding site and this would
somehow prevent replication of the unirradiated plasmid. To
test this we mixed untreated pBE102 and g-irradiated
pBluescript, which does not have the Py origin and therefore
Figure 4. p53 inhibits replication but not repair synthesis of g-irradiated Py-ori-DNA. (A) HA±p53 [¯u] protein (600 ng) was added to DNA replication reac-
tion mixtures in which plasmid pBE102 (300 ng) pre-treated with increasing dosages of g-irradiation was used as the template. (B) Effects of HA±p53 [¯u]
protein on the replication of intact pBE102, pBE102 pre-treated with 35 Gy and 70 Gy g-irradiation were compared; n = 5. (C) The replicated DNA from one
experiment in which 600 ng of HA±p53 [¯u] protein was added to the reaction mixture containing 300 ng of pBE102 pre-treated with 70 Gy g-irradiation was
puri®ed and analyzed by DpnI digestion. The DpnI-resistant DNA molecules are replication products, while the low molecular weight, DpnI-digested DNA
molecules are repair products. (D) Increasing amounts of HA±p53 [¯u] protein (200, 400 and 600 ng) were added to replication reaction mixtures with 300 ng
of g-irradiated pBE102 (70 Gy) lacking Py T antigen. DNA products were puri®ed and analyzed by DpnI digestion.
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does not support DNA replication with the Py large T antigen-
complemented in vitro DNA replication system. It was
observed that the endogenous p53 binding site and DNA
lesion(s) caused by g-irradiation do not work in trans in
making DNA replication inhibited by HA±p53 [¯u] (Fig. 6A).
Similarly, HA±p53DC30 [¯u] and the C-terminal domain of
p53 (HA±p53300±393 [¯u]), which binds preferentially to the
consensus site and DNA damage sites, respectively, do not
work in trans either (Fig. 6B).
Inhibition of the replication of g-irradiated pBE102 by
p53 takes place in the initiation stage of DNA replication
It is feasible to design in vitro replication experiments to
determine what step is being inhibited by p53. As was ®rst
demonstrated with SV40 ori-DNA replication, when reaction
mixtures are deprived of deoxynucleotides and pre-incubated
with T antigen, the pre-synthesis complex forms (47), but the
complex is unable to begin elongation. It is thus possible to
determine whether p53 inhibition of DNA replication occurs
at the elongation or initiation stage by adding it to replication
mixtures either before or after addition of deoxynucleotides.
Pre-incubation with T antigen was carried out for 10 min and
then HA±p53 [¯u] protein (600 ng) was added and incubated
for a further 10 min, followed by the addition of deoxynucle-
otides to allow elongation (Fig. 7). DNA replication after this
treatment was compared with that in replication reaction
mixtures when HA±p53 [¯u] was added without pre-
incubation (compare lane 3 with lane 5, lane 4 with lane 6).
Figure 5. Inhibition of the replication of g-irradiated Py ori-DNA requires the p53 C-terminus, as well as the endogenous p53 binding site in the Py origin.
(A) Effects of the four different forms of p53 protein shown in Figure 1A on the replication of pBE102 (70 Gy) were compared; n = 4. (B) DNA products
from one experiment using HA±p53 [PAb421] and HA±p53DC30 [¯u] were analyzed by DpnI-digestion. The lower part of the gel containing the repair
products was exposed three-times longer to autoradiography. (C) The effects of HA±p53 [¯u] protein on the replication of pBE102, pBE102BSM1 and
pBE102BSM2 were compared; n = 4.
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HA±p53 [¯u] inhibited replication of both Vw16PyCAT and
damaged pBE102 templates without T antigen pre-incubation.
When T antigen was allowed to form the pre-synthesis
complex at the origin; however, HA±p53 [¯u] was no longer
able to inhibit replication of either template (Fig. 7). The result
that inhibition of replication of both types of template happens
at the beginning of DNA replication suggests that p53 may
inhibit replication of the two different types of templates
through the same mechanism.
DISCUSSION
In this study we extended our previous conclusion that p53
must bind speci®cally to undamaged Py ori-DNA in order to
block its replication and showed that the endogenous p53
binding site adjacent to the core Py origin is essential for this
inhibition. Further, we found that DNA lesion(s) caused by
ionizing radiation can also recruit p53 and thereby facilitate its
inhibition of replication of the damaged DNA. Taken together
our results show that for the replication of Py DNA to be
inhibited by p53 protein, the endogenous p53 binding site on
the early side of the origin, as well as other strong p53
interactions with the template, are required. These interactions
can be mediated either by its central core or its C-terminal
domains.
Do our results re¯ect the possibility that virtually any DNA
binding protein when present in suf®ciently high quantities
may inhibit replication of radiation damaged ori-DNA?
Arguing against this are our results showing that (28) p53
needs to be able to interact speci®cally with the endogenous
p53 binding site on the early side of the ori as well as with
DNA lesions caused by irradiation, (i) p53 needs both its
speci®c and non-speci®c DNA binding domains to cause this
inhibition, and (ii) p53 blocks speci®cally the initiation and
not the elongation stage of ori-DNA synthesis. Thus, it is
unlikely that p53 is blocking replication by random non-
speci®c binding to the damaged DNA. It is also noteworthy
that Ito et al. (48) showed that the transcription factor AP1
stimulates the initial stage of in vitro replication of a Py ori-
DNA plasmid containing the AP1 binding site. Their result
Figure 6. DNA lesions on the template are required in cis for the replication
of pBE102 to be inhibited by p53 protein. (A) Increasing amounts of HA±
p53 [¯u] protein (200, 400 and 600 ng) were added to replication reaction
mixtures containing either 300 ng of g-irradiated pBE102 (70 Gy) or 200 ng
of untreated pBE102 together with 200 ng of g-irradiated pBluescript. DNA
products were puri®ed and analyzed by DpnI digestion. (B) Effects of the
C-terminal domain of p53 (HA±p53300±393 [¯u]), HA±p53DC30 [¯u] (200,
400 and 600 ng) or the combination of the two on the replication of g-irradi-
ated pBE102 (70 Gy) were compared with that of full-length HA±p53 [¯u];
n = 3.
Figure 7. Inhibition of the replication of both Vw16PyCAT and g-irradiated
pBE102 takes place in the initiation stage of DNA replication. Replication
reactions containing either Vw16PyCAT (lanes 1, 3 and 5) or g-irradiated
pBE102 (lanes 2, 4 and 6) were performed under two conditions: in lanes 3
and 4, 1 mg of Py T antigen was pre-incubated for 10 min with the template
plasmid (300 ng) and FM3A cell extract (400 mg) at 33°C before HA±p53
[PAb421] (600 ng) and deoxynucleotides were added to the reaction
mixtures; in lanes 5 and 6, the same amounts of T antigen and HA±p53
[PAb421] were added simultaneously into reaction mixtures. Lanes 1 and 4
are controls in which no p53 was added. Replication was determined as in
previous ®gures; n = 3.
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argues against the possibility that a sequence-speci®c inter-
actor with DNA in the vicinity of the Py ori will obligatorily
inhibit its replication.
To explain the mechanism underlying the inhibition of Py
DNA by p53, several possibilities can be suggested: (i) by
binding to ¯anking consensus sites or lesion site(s), p53 may
sequester away proteins which are essential for the replication
machinery such as RP-A and T antigen; (ii) p53 binding to a
site close to the replication origin, such as the endogenous p53
site of Py DNA, may block access of the replication initiation
complex to the origin; (iii) p53 may also function as an anti-
helicase (49) and counteract the helicase activity of T antigen
by re-annealing denatured DNA around the origin; (iv) by
binding to separate sites p53 may loop DNA around the origin
and therefore produce steric hindrance to replication initiation.
Our results presented in this paper strongly support the DNA
looping model (Fig. 8), because both the endogenous p53
binding site on the early side and an in cis p53 binding site on
the late side adjacent to the Py origin are required for the DNA
replication to be inhibited by p53. It has been shown
previously that p53 binding to separate single consensus
sequences can indeed bend and loop DNA, and DNA looping
by p53 may play an important role in transactivation of certain
promoters (50,51). So far, it remains to be tested whether p53
can also loop DNA by binding to separate DNA lesions, or as
suggested by our result, by separately binding to a consensus
sequence and a lesion site(s).
It was interesting to discover that when the endogenous p53
binding site adjacent to the Py origin was mutated to BSM1
(that cannot bind p53), the replication ef®ciency of the mutant
plasmid was increased 3±4-fold (data not shown). The fact that
the wild-type polyomavirus genome contains an endogenous
p53 binding consensus site provides the intriguing possibility
that polyomavirus may indeed use the host p53 protein to
regulate amplicational replications. Amplicational replication
of small DNA tumor viruses is normally initiated after entry of
the viral genome into the cell nucleus, which leads to a rapid
increase in copy number of the virus genome (32).
Amplicational replication of the viral genome is essential for
the establishment of viral infection but has to be controlled in
order to avoid over-replication and unscheduled death of host
cells prior to the synthesis of late genes and the production of
infectious particles. It is tempting to speculate that polyoma-
virus uses p53 as a cellular factor to control amplicational
replication. Further experiments will be required to test this
possibility. Small DNA tumor viruses generally encode
proteins that interact with and modulate the activity of p53
and thereby regulate p53-dependent apoptosis of the host
cells. For example, the large T antigen of SV40 (26,52), E1B
protein of adenovirus (53), x antigen of hepatitis B virus
(54,55) and other viral proteins interact with p53 and thereby
modulate p53-dependent apoptosis. So far no protein encoded
by the Py genome has been identi®ed that interacts with or
regulates the activity of p53 protein. It supports the likelihood
that polyomavirus uses p53 as a cellular factor to keep
amplicational replication in check.
In the original conception of p53 as a checkpoint factor, it
was proposed that DNA damage would induce a transient G1
arrest in cells with wild-type but not mutant p53 to allow time
for damaged DNA to be repaired before continuation of the
cell cycle (56). It is tempting to speculate that p53 may
participate directly in a pathway that stops or slows down
DNA replication more rapidly than the transcription-
dependent p21/E2F pathway. Although p53 is believed to
interact with various forms of DNA damage through its
C-terminus the biological function of this interaction has not
been elucidated. In our study using ionizing radiation
damaged Py ori-DNA plasmids we were able to demonstrate
by in vitro experiments a potential new function for p53,
namely that of direct inhibition of initiation of DNA replica-
tion in a DNA binding-dependent manner. It should be noted
here that a p53-dependent DNA replication checkpoint has not
been demonstrated (57), and in fact p53 has been shown to be
transcriptionally impaired when it accumulates in blocked
S-phase (30). What is not known, however, is whether at the
very onset of S-phase radiation-damaged templates might be
prevented from initiating replication as a result of direct
interactions with p53. It is acknowledged that the replication
of Py ori-DNA embodies several features that are distinct from
the as yet poorly understood process of mammalian genomic
DNA replication. Nevertheless, it is noteworthy that p53 could
Figure 8. Model showing DNA looping mediated by p53. The Py core
origin region (Origin), positioned between late and early regions, comprises
an A/T-rich stretch (A/T), a region of dyad symmetry (DYAD) containing T
antigen binding sites and an inverted repeat (IR). The endogenous p53
binding site (p53 BS) is located close to the origin (gray bar) on the early
side. p53 protein is represented by the sphere tetramers. Exogenous p53
binding sites (either sequence-speci®c sites or sites of DNA damage) are
represented by the `x's.
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only exert its effect on the initial stages of Py-ori DNA
synthesis and, once initiated, p53 was ineffective in inhibiting
ongoing replication. Thus, based both on our biochemical
observations and the existing body of knowledge of p53 in
cells, it is possible that p53 might serve to prevent the onset of
S-phase both through its function as a transcription factor and
its ability to bind to damaged DNA and prevent initiation of
DNA synthesis. Once S-phase has initiated, it would follow
that p53 would no longer be effective in inhibition of
pre-initiated replication forks, even if stalled.
It is not clear how often sequence-speci®c p53 binding sites
reside in the vicinity of mammalian replication origins. It is
intriguing, however, that the two ®rst cellular p53 binding
sites to be identi®ed were found in the vicinity of putative
human replication origins (58). The ever-increasing number of
transcriptional targets of p53 suggests that there may be large
numbers of such binding sites in the genome. Besides
polyomavirus, speci®c p53 binding sites have also been
identi®ed in the SV40 replication origin (59). It remains to be
further studied whether DNA looping by p53 occurs and, as
suggested by this study, plays functional roles regulating DNA
replication in cells.
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